$268 Billion in U.S. Life Science Investment in 2025
America leads the world in healthcare innovation and access, and a strong medical infrastructure is essential to maintain this standing for our national security.
This year, the life sciences sector has delivered.
We Work For Health is tracking every new U.S. biopharma facility announcement and news report, revealing more than $268 billion invested to drive new R&D, expand manufacturing and create jobs nationwide.
Investment in America
These investments bring cutting edge treatments closer to the patients who need them while bolstering America’s position as a world leader in healthcare access and innovation. The positive impact of these investments reaches deep into U.S. communities, with millions of high-skill positions for scientists and engineers, alongside tens of thousands of construction and support roles and millions of jobs for the communities surrounding these cutting edge faciltiies. This includes more than 4.9 million total U.S. jobs and $71.6 billion in vendor spending in states along with $2.6B in wages paid to the American construction workforce.
766%
increase in facility investment announcements versus 2024
10K+
new construction jobs across America
The biopharmaceutical industry’s investments reflect a commitment to ensuring the U.S. remains a leader in the life sciences, but China continues a coordinated campaign to dominate the life sciences, jeopardizing America’s momentum.
It’s essential to have the right policies in place that encourage continued investment to secure America’s future as the global leader in life sciences.
Faster delivery
of breakthrough medicines to patients
U.S. Life Sciences Investment Tracker:
January 12, 2026
AbbVie
$90 billion
Unspecified location
Pledging an additional $90 billion toward U.S.-based research and development and capital investments, including manufacturing, over the next decade to bring the company’s total commitment to $100 billion.
AbbVie previously committed to a $10 billion U.S. expansion in April 2025.
January 9, 2026
Novartis
Unspecified
Winter Park-FL
A new radioligand therapy (RLT) manufacturing site is expected to come online by 2029 and strengthen the company’s specialized supply chain and manufacturing capabilities across its network of RLT production facilities.
Part of a larger, previously announced $23 billion company investment.
December 9, 2025
Eli Lilly
$6 billion
Huntsville-AL
A new, next-generation active pharmaceutical ingredient (API) facility that will support the production of small molecule synthetic and peptide medicines, including an oral GLP-1. The project will bring “450 high-value jobs” to the area, including engineers, scientists, operations personnel and lab technicians, and 3,000 construction jobs.
Part of a larger, previously announced $27 billion company investment.
November 21, 2025
AstraZeneca
$2 billion
Frederick-MD, Gaithersburg-MD
Expansion of the company’s flagship biologics manufacturing facility in Frederick and the construction of a new state-of-the-art facility in Gaithersburg for the development of innovative molecules to be used in clinical trials.
The investment will support 2,600 jobs across the two sites, including the retention of local jobs, construction activity, and the creation of 300 highly skilled jobs.
Part of a larger, previously announced $50 billion company investment.
November 19, 2025
Novartis
Unspecified
Durham-NC, Morrisville-NC
A new site in Durham featuring two facilities dedicated to manufacturing biologics and sterile packaging. Also an expansion of an existing Durham facility with the added capability to support sterile filling of biologics into syringes and vials.
A new site in Morrisville with one facility for the production of solid dosage tablets and capsules, including packaging.
These investments are expected to create 700 new jobs in North Carolina by 2030 and support more than 3,000 indirect jobs across the Novartis U.S. supply chain.
Part of a larger, previously announced $23 billion company investment.
October 29, 2025
Eli Lilly
$1.2 billion
Carolina-PR
Expansion and modernization of the Lilly del Caribe manufacturing site to support the company's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology. The project will generate an estimated 1,000 construction jobs and 100 additional high-tech manufacturing positions.
Part of a larger, previously announced $27 billion company investment.
October 20, 2025
Merck
$3 billion
Elkton–VA
Broke ground on a project to enhance an existing site with a 400,000-square-foot Center of Excellence for pharmaceutical manufacturing. The facility will support small molecule manufacturing and testing and will potentially create more than 500 full-time roles as well as 8,000 construction jobs.
Part of a $70 billion U.S. investment plan.
No entries found matching your criteria. Please modify your filters.